KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Sales (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Return on Sales data on record, last reported at 2.97% in Q3 2025.

  • For Q3 2025, Return on Sales fell 143.0% year-over-year to 2.97%; the TTM value through Sep 2025 reached 1.81%, down 2.0%, while the annual FY2024 figure was 1.21%, 184.0% up from the prior year.
  • Return on Sales reached 2.97% in Q3 2025 per NKTR's latest filing, up from 3.51% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.25% in Q4 2024 and bottomed at 7.37% in Q2 2022.
  • Average Return on Sales over 5 years is 3.46%, with a median of 3.02% recorded in 2022.
  • Peak YoY movement for Return on Sales: tumbled -294bps in 2022, then soared 488bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 5.87% in 2021, then skyrocketed by 48bps to 3.02% in 2022, then surged by 43bps to 1.71% in 2023, then soared by 114bps to 0.25% in 2024, then tumbled by -1294bps to 2.97% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 2.97% in Q3 2025, 3.51% in Q2 2025, and 4.44% in Q1 2025.